id: x_waiver_obtainment_to_opioid_use_disorder_treatment_access
name: X-Waiver Obtainment â†’ Opioid Use Disorder Treatment Access
from_node:
  node_id: x_waiver_obtainment
  node_name: X-Waiver Obtainment
to_node:
  node_id: opioid_use_disorder_treatment_access
  node_name: Opioid Use Disorder Treatment Access
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: X-waiver authorization allows clinicians to legally prescribe buprenorphine
  in office-based settings'
- 'Step 2: Increased number of waivered clinicians expands geographic availability
  of evidence-based medication treatment'
- 'Step 3: Office-based treatment reduces barriers compared to specialty opioid treatment
  programs (reduced stigma, integrated care)'
- 'Step 4: However, only 36% of waivered clinicians actually prescribe, limiting realized
  impact on treatment access'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: H. Lanham et al. 2022. "Survey of Barriers and Facilitators to
    Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment
    Act of 2000 Waiver." *JAMA Network Open*. https://doi.org/10.1001/jamanetworkopen.2022.12419
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.714291'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: professional_support_availability
  direction: strengthens
  strength: strong
  description: Availability of mentorship and peer support networks significantly
    increases likelihood that waivered clinicians actually prescribe
- name: referral_network_density
  direction: strengthens
  strength: moderate
  description: Robust referral networks for comprehensive services increase clinician
    willingness to prescribe
